Blog Archives - Myriad RBM
  • Subscribe to our Blog

    Receive excerpts from our latest posts via email.

  • Categories


    IL-10 (AM0010) phase I trial offers novel mechanism for immune-oncology drugs in solid tumors

    More commonly known as an inhibitory cytokine, high doses of IL-10 have been shown to lead to the activation and survival of antigen stimulated CD8 T cells. According to a study published in the Journal of Clinical Oncology, the investigators in this first-in-human, phase 1 clinical trial of IL-10 (AM0010), demonstrate antitumor activity and therapy […]

    » Read this post

    TruCulture and Gene Expression Profiling Characterizes Immune Responses in Landmark Study Led by Institut Pasteur

    Published in the September 6, 2016 issue of Cell Reports, Standardized Whole-Blood Transcriptional Profiling Enables the Deconvolution of Complex Induced Immune Responses describes the use of the Myriad RBM TruCulture® platform for standardized ex vivo immune stimulation and a high-throughput method for gene expression profiling to explore immune variance within a population. Standardized Whole-Blood Transcriptional […]

    » Read this post

    DNA variants correlated with blood based biomarkers may predict disease features within COPD

    By Sam LaBrie   Developing precision medicines for COPD is an important goal, as the disease is the third most common cause of death in the developed world and there are relatively few effective therapies. A recent study published in PLOS, Common Genetic Polymorphisms Influence Blood Biomarkers Measurements in COPD, explores the massive datasets from […]

    » Read this post

    Monitoring differences in the innate and adaptive immune response in Amish and Hutterite children

    By Ralph McDade Let your kids get dirty; it’s good for them! In the current issue of the New England Journal of Medicine researchers explore the mechanism behind the effect of endotoxin exposure on asthma and allergies in children. The researchers used Myriad RBM’s TruCulture® tubes to collect and stimulate whole blood in order to […]

    » Read this post

    Researchers in this immuno-oncology trial used Myriad RBM’s services to measure serum biomarkers.

    Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma The data presented in this paper shows baseline and on-treatment biomarkers from a phase 1b study of the PD-1 inhibitor nivolumab in renal cell carcinoma. The study examined immune changes in the microenvironment of the tumor, such as types of tumor infiltrating cells and gene expression […]

    » Read this post

    Impressions from Biomarkers and Diagnostics World Congress 2016

    Our sales and marketing team represented Myriad RBM at the Biomarkers and Diagnostics World Congress in Philadelphia with a booth on the vendor floor. In addition to hearing the latest in the world of biomarker development, we had a chance to chat to current customers and introducing new ones to our biomarker testing services. Of […]

    » Read this post

    Myriad RBM’s DiscoveryMAP® Identifies a Protein Biomarker Panel for Bipolar Disorder

    Researchers at the Mayo Clinic used Myriad RBM’s Multi-Analyte Profile (MAP) platform to analyze 320 serum proteins in healthy control subjects and subjects with mood disorders. A panel of 6 biomarkers was determined to reliably differentiate between the healthy controls and mood disorder cohorts. While additional studies are still needed, this initial data holds great […]

    » Read this post

    Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia

    An international team of researchers used Myriad RBM’s Multi-Analyte Profile (MAP) technology to identify a pattern of cardiometabolic biomarkers that appears to predict cardiovascular outcomes in patients with dysglycemia. This data, the latest publication stemming from the landmark Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial, holds great promise for prognosis and treatment of patients […]

    » Read this post

    Use of biomarkers to guide immunotherapy drug development

    VentiRx, the developers of motolimod, a TLR8 agonist, have published preclinical and clinical results that indicate effective immune system stimulation in human whole blood cultures, non-human primates, healthy subjects, and late-stage cancer patients. Immune system stimulation in all of these settings is dose-dependent, characterized by similar biomarkers, and consistent with stimulation via the TLR8 pathway. […]

    » Read this post

    New serum biomarkers found to be associated with the progression of chronic kidney disease in patients with type 2 diabetes

    European researchers identified a panel of 14 serum biomarkers that improved the prediction of progression of chronic kidney disease (CKD) in patients with type 2 diabetes. Using Myriad RBM’s services, as well as other protein detection methods, the researchers measured a total of 207 serum proteins and successfully identified several new associations of biomarkers indicative […]

    » Read this post